| OVARIAN Non-commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| HE4-FU-OVCA/ CEEGOG OX-01 documents available here |
The Role of HE4 in the Follow-up of Advanced Ovarian, Fallopian Tube and Primary Peritoneal Cancer A prospective multicentre observational study The target size of the group: 150 patients |
Ongoing |
| ATALANTE/ ENGOT-ov29/GINECO |
A randomized, double blinded, phase III study of Atezolizumab versus placebo in patients with late relapse of epithelial ovarian, fallopian tube, or peritoneal cancer treated by platinum-based chemotherapy and Bevacizumab The target size of the group: 600 patients |
Enrollment closed |
| EXPRESSION VI/ ENGOT-ov40/NOGGO S13 |
Caroline meets HANNA – Holistic Analysis of longterm survivors with ovarian cancer The target size of the group: 100-200 per participating country |
Ongoing |
| MITO33/ ENGOT-ov51 |
A Randomized phase III trial on Niraparib-TSR 042 vs physician’s choice chemotherapy in recurrent, ovarian, fallopian tube or primary peritoneal cancer patients not candidate for platinum retreatment The target size of the group: 427 |
Under preparation |
| CERVICAL Non-commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| SENTIX/ CEEGOG CX-01/ ENGOT-cx2 documents available here |
Sentinel node in cervix cancer A prospective observational trial on sentinel lymph node biopsy in patients with early stage cervical cancer The target size of the SLN Study group: 600 patients The target size of the Control group: 100 patients Estimated enrollment period: 2016 – 2020 |
Ongoing |
| FERTISS/ CEEGOG CX-03 documents available here |
FERTIlity Sparing Surgery in cervical cancer patients outside controlled trials | Ongoing |
| CERVANTES/ CEEGOG CX-05 |
A prospective randomized trial on the role of radical surgery and adjuvant therapy in the management of intermediate risk cervical cancer patients. The target size of the group: TBD |
Under preparation |
| RSS-EAC-PAT/ CEEGOG CX-04 documents available here |
The Risk Stratification System for endocervical adenocarcinoma based on tumor pattern and its clinical outcomes | Closed |
| ABRAX/ CEEGOG CX2/ ENGOT-cx3 documents available here |
Oncological outcome after completing or abandoning (radical) hysterectomy in patients with cervical cancer and intraoperative detection of LN positivity | Closed |
| SALVAGE/ CEEGOG EX01 |
A retrospective trial on patients who have undergone salvage surgery for a recurrent uterine or cervical cancer Salvage database – data from 620 patients collected, currently results analysed |
Closed |
| ENDOMETRIAL Non-commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| TESLA1/ CEEGOG EX-02 |
Tracers for Endometrial cancer Sentinel node LAbelling A Prospective observational study on sentinel node biopsy using two concurrent labelling techniques (radioactive tracer with/without blue dye vs. indocyanin green-ICG) in early-stage endometrial cancer patients The target size of the group: 92 patients |
Under preparation |
| ENGOT-EN2-DGCG/ EORTC 55102 |
A phase II Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer The target size of the group: 240 patients |
Enrollment closed |
| OVARIAN Commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| MK-7339-001-00/ ENGOT-ov43/BGOG |
A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA non-mutated Advanced Epithelial Ovarian Cancer (EOC) The target size of the group: 1086 patients |
Ongoing |
| INNOVATE-3/ ENGOT-ov50/BGOG |
Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 200kHz) concomitant with weekly paclitaxel for the treatment of platinum-resistant ovarian cancer (PROC) The target size of the group: 540 patients |
Ongoing |
| FIRST ENGOT-ov44/GINECO |
A Patient‑centric, Randomized, Phase 3 comparison of Platinum‑based Therapy with or without bevacizumab to the same plus TSR‑042 as first‑line treatment of stage iii or iv non-mucinous ovarian cancer followed by maintenaNce therapy The target size of the group: 720 - 960 patients |
Ongoing |
| ATHENA/ ENGOT-ov45/NCRI |
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy The target size of the group: 1000 patients |
Ongoing |
| MIRASOL/ ENGOT-ov55/ BGOG |
A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression The target size of the group: 430 patients |
Under preparation |
| SOV09/VITALIA/ ENGOT-ov53/CEEGOG |
A phase III, multicentre, randomized, double-blind, placebo-controlled trial of DCVAC/OvCa added to standard of care induction and maintenance therapy in patients with relapsed platinum-sensitive ovarian, fallopian tube, and primary peritoneal carcinoma The target size of the group: 678 patients |
Under preparation |
| SOTIO/ SOV01 |
SOV01 A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with newly diagnosed epithelial ovarian carcinoma The target size of the group: additional 30 patients |
Enrollment closed |
| SOTIO/ SOV06 |
SOV06 An open-label, single-group, multicenter phase II clinical trial evaluating the effect of maintenance DCVAC/OvCa after standard of care therapy in women with first relapse of platinum-sensitive epithelial ovarian carcinoma The target size of the group: 30 patients |
Enrollment closed |
| IMAGYN050/ YO39523/GOG-3015/ ENGOT-ov39 |
A phase III, multicenter, randomized study of Atezolizumab versus placebo administered in combination with Paclitaxel, Carboplatin, and Bevacizumab for patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer The target size of the group: 1300 patients |
Enrollment closed |
| PRIMA/ ENGOT-ov26/GEICO/1509 |
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Studyof Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy The target size of the group: 620 patients |
Enrollment closed |
| JAVELIN OVARIAN 200 | A phase 3, multicenter, randomized, open-label study of Avelumab (MSB0010718C) alone or in combination with Pegylated liposomal Doxorubicin versus Pegylated Liposomal Doxorubicin alone in patients with platinum-resistant/refractory ovarian cancer Approximately 550 patients will be randomized |
Enrollment closed |
| SOTIO/ SOV02 |
SOV02 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with relapsed platinum sensitive epithelial ovarian carcinoma | Closed |
| SOTIO/ SOV03 |
SOV03 A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/ OvCa to standard chemotherapy in women with relapsed platinum resistant epithelial ovarian carcinoma | Closed |
| MILO/ ENGOT-ov11/BGOG |
MEK Inhibitor in Low-grade Serous Ovarian Cancer A Multinational, Randomized, Open-label Phase 3 Study of MEK162 vs. Physician’s Choice Chemotherapy in Patients with Recurrent or Persistent Low-grade Serous Carcinomas of the Ovary, Fallopian Tube or Primary Peritoneum |
Closed |
| NOVA/ ENGOT-ov16/NSGO |
Niraparib in OVArian cancer A randomized, double-blind phase 3 trial of maintenance with niraparib vs placebo in patients with platinum-sensitive recurrent ovarian cancer |
Closed |
| CERVICAL Commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| GCT1015-05/ ENGOT-cx8/BGOG |
A Phase 2 Open-Label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) alone or in Combination in First Line Recurrent or Stage IVB Cervical Cancer The target size of the group: 140 patients |
Ongoing |
| GCT1015-07/ ENGOT-cx12/BGOG |
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer The target size of the group: 486 patients |
Under preparation |
| FERMATA/ ENGOTcx13/AGO |
An International Randomized Double-blind Clinical Trial of BCD-100 Plus Platinum-based Chemotherapy with and without Bevacizumab versus Placebo Plus Platinum-based Chemotherapy with and without Bevacizumab as First-Line Treatment of Subjects with Advanced Cervical Cancer The target size of the group: 316 patients |
Under preparation |
| KEYNOTE-A18/ ENGOT-cx11/MITO |
A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer The target size of the group: 980 patients |
Under preparation |
| GCT1015-04/ ENGOT-cx6/BGOG |
A Single arm, Multicenter, Phase 2b Trial Investigating the Efficacy of Tisotumab Vedotin (HuMax®‑TF‑ADC) Therapy in Previously treated Patients with Recurrent or Metastatic Cervical Cancer The target size of the group: 100 patients |
Enrollment closed |
| ENDOMETRIAL Commercial trials | ||
|---|---|---|
| Trial | Study description | Status |
| SIENDO/ ENGOT-EN5/BGOG-EN5 |
A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/ Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer. The target size of the group: 192 patients |
Ongoing |
| RUBY/ ENGOT EN-6/NSGO |
A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-paclitaxel versus Placebo plus Carboplatin-paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY) The target size of the group: 470 patients |
Ongoing |